Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + trastuzumab
- Development stage
- Phase 4
- Lead developer
- Genentech
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Paclitaxel + trastuzumab is a combination therapy used primarily to treat HER2-positive breast cancer. Paclitaxel is a chemotherapy agent classified as a taxane that disrupts microtubule function, inhibiting cell division and leading to cancer cell death. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2) on the surface of certain cancer cells, blocking signaling pathways that promote tumor growth and survival. This combination is commonly used in early-stage and metastatic HER2-positive breast cancers as adjuvant or neoadjuvant therapy. The regimen may be referred to as "TH" (Taxol/Herceptin), with paclitaxel administered intravenously weekly for 12 weeks alongside trastuzumab; after this period, trastuzumab alone may continue for up to one year[4][6][8][9].
- Brand names
- Taxol + HerceptinTH regimen
- Other names
- THpaclitaxel and trastuzumabTaxol + Herceptin
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + trastuzumab.